The registration of new medicines in Spain is growing. Last year, more 17% products were authorized than in 2009, according to data from the regulatory agency. And a large chunk, equal to 72%, of these new entries is made up of generic medicines.
In its annual report (relating to 2010), the National Agency for Medicines and Medical Devices (Aemps), states that it authorized 1,629 generic drugs in the course of the past year, against only 315 innovative products.
Results that follow an ever-growing trend in licensing, led by generic drugs. A surge that began in 2006, when 930 generics were approved in the country against 285 'designer brands'. The highest number of authorizations last year, if the therapeutic category is taken into consideration, concerned treatments for the central nervous system: 372 registrations, equal to 27.25% of the total. Cardiovascular medicines follow (313, equal to just under 23%); those oncology (143, 10,48%); those for gastrointestinal and metabolism (143, 10,48%), those for infectious diseases (108, 7,91%).
Margherita Lopes – May 2, 2011 – Pharmakronos
Recordati launches drug pitavastatin in Spain
MILAN, May 2nd (Reuters) – Recordati (RECI.MI: Quotation) launches pitavastatin in Spain, where it will be marketed by the local subsidiary under the brand name Livazo and by partner Esteve under the brand name Alipza.
Pitavastatin is a statin indicated for the reduction of elevated levels of total cholesterol and LDL cholesterol in adult patients with primary hypercholesterolemia and dyslipidemia combined.
Pitavastatin is licensed to Recordati by the European subsidiary of Kowa and has been on the market in the USA since 2010.
At around 10.40, the Recordati share gained 0.35%, at 7.17 euros, after having reached a maximum of 7.19 euros. Recordati is close to the highs for the year (7.25 euros).
